Abbott Laboratories


+3.66 (+0.04%) Today
1 Day1D

5 Days5D

1 Month1M

6 Months6M


1 Year1Y

2 Years2Y

5 Years5Y



Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure, and other medical device products. The Other segment comprises of Abbott Medical Optics. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.


Miles D. White




100 Abbott Park Road Abbott Park, IL, 60064-6400



Market Cap

Abbott Laboratories News

Abbott accuses former employee of masquerading as COVID-19 test salesman Oct 21, 2020

Abbott Laboratories has sued a former employee for trademark infringement and theft of trade secrets, accusing him of selling other manufacturers’ COVID-19 tests on behalf of Abbott. Attorneys for Abbott filed the complaint on Tuesday, seeking a preliminary injunction against Justin Brown as well as monetary damages. Abbott said it fired Brown from his sales […]

COVID-19 diagnostics sales boost Abbott’s Q2 results Jul 16, 2020

Abbott (NYSE:ABT) beat the consensus forecast on Wall Street today — with sales of molecular diagnostics including COVID-19 tests more than tripling. The Abbott Park, Ill.-based healthcare giant reported profits of $537 million or 57¢ per share, on sales of $7.33 billion for the three months ended June 30, 2020, for a bottom-line plunge of –47% […]

ESC Congress 2019: Biotronik beats Abbott at target lesion failure Sep 03, 2019

Biotronik said yesterday that its Orsiro stent tops the Xience stents made by Abbott (NYSE:ABT) when it comes to target lesion failure, according to data from a clinical trial. The randomized, controlled BioSTEMI trial was the first direct comparison between the two drug-eluting stents in patients with acute ST-segment elevation myocardial infarction (STEMI). Biotronik announced […]

Study: Vital Organs Support Systems and Medical Bionics Market to Reach $59.41 Billion by 2025 Jun 07, 2019

Allied Market Research published a report, titled, “Vital Organs Support Systems and Medical Bionics Market by Product (Vital organs support systems and Medical Bionics) and End User (Hospitals, Ambulatory Surgical Centers, and Others): Global Opportunity Analysis and Industry Forecast, 2018–2025.” The report offers a detailed analysis of top investment pockets, top winning strategies, drivers & opportunities, market size…

Judge: Ex-Abbott worker can’t sue twice May 10, 2019

A federal judge in Massachusetts yesterday shot down a second lawsuit brought against Abbott (NYSE:ABT) by a former medical liaison over her claim that the company fired her after she blew the whistle on off-label and pre-approval stent promotion. Ebonia Elliott-Lewis, formerly a regional science manager for Abbott Vascular based in Boston, first sued the company […]